OCUL JPM Presentation (Jan 2025).pdf

1、Ocular Therapeutix Corporate Overview43rdAnnual J.P.Morgan Healthcare Conference|January 2025Retina experience redefined.2Forward Looking Statements and Disclaimers2Any statements in this presentation about future expectations,plans,and prospects for the Company,including the development and regulat

2、ory status of the Companys product candidates,including the design of,and the timing of the enrollment of the Companys SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI(also called OTX-TKI)for the treatment of wet AMD;the Companys plans to advance the development of AXPAXLI and its other product ca

3、ndidates,including in additional indications such as NPDR;the size of potential markets for the Companys product candidates;the potential utility or adoption,if approved,of any of the Companys product candidates;the sufficiency of the Companys cash resources;and other statements containing the words

4、 anticipate,believe”,estimate”,expect”,intend,“designed”,goal”,may,might”,plan”,predict”,project”,target”,potential”,will”,would”,could”,should”,continue”,and similar expressions,constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.Actual r

5、esults may differ materially from those indicated by such forward-looking statements as a result of various important factors.Such forward-looking statements involve substantial risks and uncertainties that could cause the Companys preclinical and clinical development programs,future results,perform

6、ance,or achievements to differ significantly from those expressed or implied by the forward-looking statements.Such risks and uncertainties include,among others,the timing and costs involved in commercializing DEXTENZA or any product or product candidate that receives regulatory approval;the ability